Basal and Meal-Stimulated Ghrelin, PYY, CCK Levels and Satiety in Lean Women With Polycystic Ovary Syndrome: Effect of Low-Dose Oral Contraceptive

Arusoğlu, Gülcan; Köksal, Gülden; Çınar, Neşe; Tapan, Serkan; Aksoy, Duygu Yazgan; Yildiz, Bülent O.

doi:10.1210/jc.2013-1526

Cited by 24 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for the role of other gastrointestinal peptides in women with PCOS, results are mixed about GIP secretion, while basal and meal-stimulated levels of CCK have been found to be similar in women with PCOS as compared with BMI-matched controls ( 67 , 68 ). Similar basal and postprandial PYY levels in women with PCOS compared with BMI-matched healthy women have also been frequently reported ( 67-70 ).…”

Section: Gut-brain Axis Role In Pcosmentioning

confidence: 99%

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

Cena

Chiovato

Nappi

2020

The Journal of Clinical Endocrinology &Amp; Metabolism

189

104

View full text Add to dashboard Cite

Context Obesity is responsible for an increased risk of sub-fecundity and infertility. Obese women show poorer reproductive outcomes regardless of the mode of conception, and higher body mass index (BMI) is associated with poorer fertility prognosis. Polycystic ovary syndrome (PCOS) is one of the leading causes of infertility, and many women with PCOS are also overweight or obese. Evidence Acquisition The aim of the present narrative review is to describe the mechanisms responsible for the development of infertility and PCOS in women with obesity/overweight, with a focus on the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) as a therapeutic option for obese women with PCOS. Evidence synthesis Weight reduction represents the most significant factor affecting fertility and pregnancy outcomes. Current experimental and clinical evidence suggests the presence of an underlying pathophysiological link between obesity, GLP-1 kinetic alterations, and PCOS pathogenesis. Based on the positive results in patients affected by obesity, with or without diabetes, the administration of GLP-1 RA (mainly liraglutide) alone or in combination with metformin has been investigated in women with obesity and PCOS. Several studies demonstrated significant weight loss and testosterone reduction, with mixed results relative to improvements in insulin resistance parameters and menstrual patterns. Conclusions The weight loss effects of GLP-1 RA offer a unique opportunity to expand the treatment options available to PCOS patients.

show abstract

Section: Gut-brain Axis Role In Pcosmentioning

confidence: 99%

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

Cena

Chiovato

Nappi

2020

The Journal of Clinical Endocrinology &Amp; Metabolism

189

104

View full text Add to dashboard Cite

show abstract

“…A total of 20 reports met the inclusion criteria and were included in this study(11, 24–41). Since several studies reported the estimates separately according to different categories of BMI (<25 or ≥25), we treated them as from separate studies and incorporated all in the pooling analysis(25, 26, 30, 32, 35, 41).…”

Section: Resultsmentioning

confidence: 99%

“…For 16 included studies(12, 24–29, 31–34, 36–39, 41), the diagnosis of PCOS was based on the revised 2003 consensus on diagnostic criteria of PCOS by Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (42). In these studies all PCOS patients met at least 2 of the required 3 criteria as: 1).…”

Section: Resultsmentioning

confidence: 99%

Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta-analysis

Gao

Chang

et al. 2016

Endocr J

View full text Add to dashboard Cite

Although numerous, human subject studies evaluating the relationship between circulating ghrelin levels and polycystic ovary syndrome (PCOS) risk have yielded inconsistent findings. We aimed to quantitatively assess the association by summarizing all available evidence from human subject studies. The PubMed and Web of Science databases were searched up to February 2015 for eligible studies. Studies were eligible if they reported circulating ghrelin levels in women with PCOS and healthy women controls. A fixed or random-effects model was used to pool risk estimations. Twenty studies including 894 PCOS patients and 574 controls were included in the meta-analysis. The studies had fair methodological quality. The pooling analysis of all available studies revealed that ghrelin levels were significantly lower in PCOS patients than in controls, with standardized mean difference of −0.40 (95% CI: −0.73, −0.08). The significant association persisted in many subgroup strata. However, the heterogeneity across studies was considerable and not eliminated in subgroup analyses. Meta-regression analysis further suggested that the heterogeneity might be relevant to variability in study location, PCOS relevant factors like HOMA-IR ratio, as well as other factors not assessed. In conclusion, our meta-analysis suggested that ghrelin levels were significantly lower in PCOS patients than in controls. Further studies with large sample sizes are warranted to replicate our findings.

show abstract

“…There is no study investigating caloric intake in women with PCOS. While several studies have reported decreased meal-stimulated and/or basal ghrelin levels in women with PCOS [68–70], there is no convincing evidence for differences in satiety among affected women [68, 69]. …”

Section: Metabolic Phenotype In Pcosmentioning

confidence: 99%

Cardiometabolic Risk in PCOS: More than a Reproductive Disorder

Torchen

2017

Curr Diab Rep

View full text Add to dashboard Cite

Purpose of Review Polycystic ovary syndrome (PCOS) is diagnosed by its characteristic reproductive features. However, PCOS is also associated with metabolic abnormalities, including insulin resistance and β-cell dysfunction. The severity of these abnormalities varies according to the reproductive phenotype, with the so-called NIH or classic phenotype conferring the greatest metabolic risk. The increased risk for type 2 diabetes (T2D) is well-established among affected women with the NIH phenotype, but whether PCOS also confers an increased risk for cardiovascular events remains unknown. Recent Findings Recent studies in daughters of affected women have found evidence for pancreatic β-cell dysfunction prior to menarche. Further, genetic analyses have provided evidence that metabolic abnormalities such as obesity and insulin resistance contribute to the pathogenesis of PCOS. Summary PCOS increases the risk for T2D. However, the risk for cardiovascular disease has not been quantified, and prospective, longitudinal studies are still critically needed.

show abstract

Basal and Meal-Stimulated Ghrelin, PYY, CCK Levels and Satiety in Lean Women With Polycystic Ovary Syndrome: Effect of Low-Dose Oral Contraceptive

Abstract: Basal and stimulated hunger and satiety hormones in lean PCOS patients are not different from lean healthy women, except for a lower meal-stimulated ghrelin response. Short-term use of a low-dose oral contraceptive does not have an effect on appetite regulation of PCOS.

Cited by 24 publications

References 38 publications

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta-analysis

Cardiometabolic Risk in PCOS: More than a Reproductive Disorder

Contact Info

Product

Resources

About